Protheragen Obesity



Palosuran

Cat. No.:	OB0225WX-2261
Appearance:	Solid
Purity:	≥98%
Identity:	Confirmed by NMR, and LC-MS.
Size:	2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	Palosuran is a potent and specific small molecule antagonist targeting the human urotensin-II (UT) receptor.
Synonym	ACT-058362; 540769-28-6; 1-(2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea; ACT058362 (Palosuran); 1-[2-(4-benzyl-4-hydroxypiperidin-1 -yl)ethyl]-3-(2-methylquinolin-4-yl)urea; Urea, *N*-[2-[4-hydroxy-4-(phenyl Methyl)-1-piperidinyl]ethyl]-N'-(2-Methyl-4-quinolinyl)-; 1-(2-(4-Benzyl-4-hydro xypiperidin-1-yl)ethyl-3-(2-methylquinolin-4-yl)urea; 1-[2-[4-hydroxy-4-(phenylm ethyl)piperidin-1-yl]ethyl]-3-(2-methylquinolin-4-yl)urea; Urea, *N*-(2-(4- hydroxy-4-(phenylmethyl)-1-piperidinyl)ethyl)-N'-(2-methyl-4-quinolinyl)-; palos uranum; 1-(2-(4-hydroxy-4-(phenylmethyl)piperidin-1-yl)ethyl)-3-(2-methylquinoli n-4-yl)urea; ACT 058362; ACT 058362; Palosuran; 1-(2-(4-benzyl-4-hydroxypiperidi n-1-yl)ethyl)-3-(2-methylquinolin-4-yl)urea sulfate salt; 1-[2-(4-Benzyl-4-hydro xy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea
CAS No.	540769-28-6
Compound CID	10173280
Formula	$C_{25}H_{30}N_4O_2$
Formula Weight	418.53

Specification

Targets&IC50	UT receptor (human): 3.6±0.2 nM

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com

Protheragen
Obesity



Relative Density	1.235 g/cm^3
IUPAC Name	1-[2-(4-Benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(2-methylquinolin-4-yl)urea
InChI	InChI=1S/C25H30N4O2/c1-19-17-23(21-9-5-6-10-22(21)27-19)28-24(30)26-13-16-29-14-11-25(31,12-15-29)18-20-7-3-2-4-8-20/h2-10,17,31H,11-16,18H2,1H3,(H2,26,27,28,30)
InChI Key	WYJCYXOCHXWTHG-UHFFFAOYSA-N
SMILES string	CC1=NC2=CC=CC=C2C(=C1)NC(=O)NCCN3CCC(CC3)(CC4=CC=CC=C4)O
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Palosuran is utilized in cardiovascular and renal research as a potent and selec tive urotensin II receptor antagonist to investigate the role of the urotensin s ystem in vascular tone and fibrotic disease progression.

Library Information

Target	Urotensin receptor
Receptor	Urotensin receptor
Pathways	Endocrinology/Hormones; GPCR/G protein signaling
Plate Number	AOCL-29
Plate Location	h8
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	55 mg/mL; 131.41 mM

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com